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Alveolar soft part sarcoma (ASPS) is a rare malignant neo-
plasm of the head and neck region of uncertain histogenesis.
ASPS commonly originates in the head and the neck region
with 25% of the cases occurring in the tongue.1,2 ASPS pre-
sents as a slow-growing, painless mass that occurs in female
patients between 15 and 35 years old.2,3 Metastasis occurs
in the lungs, brain or bones and the prognosis is unfavour-
able.2 The aim of this paper is to report an additional case
of ASPS on the tongue in a 17-year-old girl.741-9409/$ - see front matter c 2006 Elsevier Ltd. All rights reserved
oi:10.1016/j.ooe.2006.02.001
* Corresponding author. Tel.: +55 31 3499 2477; fax: +55 31 3499
472.
E-mail address: rsgomez@ufmg.br (R. Santiago Gomez).Case report
A 17-year-old girl was referred to the Oral Diagnosis Section,
Odilon Berhens Hospital with a swelling on the tongue of
three months duration (Fig. 1(A)). Extraoral examination re-
vealed neither facial alterations nor cervical node enlarge-
ment. Intraoral examination showed a nodule at the
dorsum surface of the tongue, asymptomatic, elastic consis-
tency, measuring 2 cm in diameter and covered by a mucosa
of normal colour and texture. The fine needle aspiration was
negative for liquid. Clinical diagnosis was benign mesenchy-
mal neoplasm (neurofibroma, schwannoma and lipoma). An
excisional biopsy was performed under local anesthesia.
The surgical specimen was fixed in 10% neutral phosphate-
buffered formalin.
Histological findings showed nests of large granular cells
separated by fibrovascular stroma (Fig. 1(B) and (C)). The.
Figure 1 (A) Clinical aspect of the lesion. (B and C) Microscopic view showing nests of large granular cells separated by
fibrovascular stroma (hematoxylin-eosin stain, original magnification x40 and x100). (D) Tumoural cells with intracytoplasmic PAS-
positive granules and roads (PAS with diastase pretreatment). Positive immunostaining for enolase (E) and smooth muscle actin
(F) (Streptavidin-biotin-complex stain, original magnification x100).
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lar eosinophilic cytoplasm and vesicular nuclei with small
nucleoli. Mitotic figures and nuclear pleomorphism were
not present. Periodic acid-Schiff (PAS) with and without
diastase digestion demonstrated deposits of intracellular
glycogen and rhomboid shaped crystals (Fig. 1(D)). Cross-
striations were not identified with the phosphotungstic
acid-hematoxylin or Masson tricrome staining, respectively.
Immunohistochemical performed on formalin-fixed, par-
affin-embedded tumour tissue revealed few tumour cells
positive for the antibodies against muscle specific actin
(Clone HHF-35, diluted 1:100, DAKO Corporation), cytoplas-
mic (but not nuclear) reactivity for MyoD1 (5-BA, diluted
1:100, DAKO Corporation) and myogenin (Clone F5D, diluted
1:100, DAKO Corporation). Strong staining was observed for
desmin (Clone A0611, diluted 1:50, DAKO Corporation), neu-
ron-specific enolase protein (NSE) (Clone A0587, diluted
1:100, Dako Corporation) (Fig. 1(E)) and smooth muscleactin (Clone 1A4, diluted 1:50, DAKO Corporation)
(Fig. 1(F)). No immunoreactivity was seen for vimentin
(Clone Vim 3B4, diluted 1:100, DAKO Corporation), S-100
(Z0311, diluted 1:75, DAKO Corporation), cytokeratin AE1/
AE (Clone AE1 & AE3, diluted 1:50, DAKO Corporation). Anti-
gen retrieval with citrate buffer (0.01 M, pH 6.0, 95,
30 min) was performed to all the antibodies, except to
S-100. Diagnosis of the ASPS, solid pattern, was made. The
patient was referred to the Oncology Service for further
evaluation and no metastatic lesion was detected.Discussion
ASPS is a rare malignant tumour corresponding to less than
1% of all soft tissues sarcomas.3,4 The lower extremities are
the most common location, but it also occurs in the head
and neck region (27%), with 25% of the cases affecting the
Alveolar soft part sarcoma of the tongue 243tongue.3,5,6 The age for lingual ASPS is much younger than
that for ASPS in other anatomical locations.7,8 Lingual ASPS
are reported in patients less than 21 years of age with a fe-
male predilection of 2:1.1,9
Microscopic features, histochemical and immunohisto-
chemical are important to the definitive diagnosis of ASPS.
The cells reveal varying amounts of intracellular glycogen
and characteristically PAS-positive, diastase-resistant
rhomboid or rod-shaped crystals.1,6,7 In our case, the cells
were PAS-positive and showed diastase-resistant crystals
in the cytoplasm. This aspect has been observed in 80% of
cases in others studies, and is helpful to differentiate this
tumour from rhabdomyoma.10 Rhabdomyoma present cells
PAS-positive, but the intracitoplasmatic glycogen granules
disappeared after pretreatment with diastase.1,11,12 Fur-
thermore, rhabdomyoma shows cross-striations in phospho-
tungstic acid-hematoxylin and Masson tricrome staining.13
Since its first description, ASPS has been object of debate
and controversy.4 Despite earlier attempts to prove a neuro-
ectodermal, endocrine or myogenic lineage of differentia-
tion in this neoplasm, its histogenesis has not been
established.9,14,15 Although the immunohistochemical profile
indicates a myogenic origin, it does not present consistent
findings.2 The cells of the tumour do not stain with anti-
bodies against cytokeratin, epithelial membrane antigen,
neurofilaments, glial fibrillary acidic protein, serotonin, syn-
aptophysin, met-enkephalin and leu-enkephalin, but occa-
sionally express S-100 protein and NSE.7 In our case the
neoplasic cells were positive to NSE and negative to S-100.
Musclemarkers differ somewhat, butmost investigatorswere
able to demonstrate immunoreactivity for vimentin, muscle-
specific actin and desmin. Negative staining for vimentin has
also been reported.1,16,17 Among the muscle markers that we
investigated, desmin was strongly positive. Among specific
markers of myogenous differentiation, negative and positive
labeling is described for myoglobin and myogenin, respec-
tively.7,9,13,14,16,18 While MyoD1 shows nuclear staining in
muscle cells, positive cytoplasmic labeling is observed on
the tumoural cells in ASPS and is considered negative.13
Histologic parameters such as atypia, cellularity, necro-
sis, and number of mitosis per high power field seem to rep-
resent the most reliable criteria of malignancy of soft tissue
sarcoma. However, these parameters are imprecise and
subjective for predicting clinical behaviour of ASPS and
may cause diagnostic confusion with other diseases.6,7
ASPS is characterized by relatively slow grow and seldom
recurs locally after complete resection; however, it pre-
sents a high rate of metastasis.3,19 The main sites of metas-
tasis are lung, bone, and brain.1 While recurrences or
metastasis were reported in 30% of lingual ASPS in one
study6, only one out of 10 patients presented lung metasta-
sis in another one.8 Therefore patients with lingual ASPS
may be follow-up for long time.
Treatment of lingual ASPS includes surgical excision,
sometimes combined with adjuvant radiotherapy or chemo-
therapy.1,7 According to a series of cases reported, adjuvant
therapy may not be necessary if the small primary lingual
ASPS can be completely resected and the patient does not
experience clinical recurrence or metastasis.7 The survival
for patients with no evidence of metastasis at the time of
diagnosis is 60.0% at 5 years, 38.0% at 10 years, and 15.0%at 20 years.13 Prognostic factors are patient’s age, tumour
size, and the presence of metastasis at diagnosis. In con-
trast to ASPS in other parts, lingual ASPS have a good prog-
nosis.7 In the present case no evidence of metastasis or
recurrence was observed after one year.
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